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ABSTRACT
Aim: VE1 is a monoclonal antibody detecting mutant BRAFV600E protein by 
immunohistochemistry. Here we aim to determine the inter-observer agreement and 
concordance of VE1 with mutational status, investigate heterogeneity in colorectal 
cancers and metastases and determine the prognostic effect of VE1 in colorectal cancer 
patients. Methods: Concordance of VE1 with mutational status and inter-observer 
agreement were tested on a pilot cohort of colorectal cancers (n = 34), melanomas 
(n = 23) and thyroid cancers (n = 8). Two prognostic cohorts were evaluated (n = 
259, Cohort 1 and n = 226, Cohort 2) by multiple-punch tissue microarrays. VE1 
staining on preoperative biopsies (n = 118 patients) was compared to expression 
in resections. Primary tumors and metastases from 13 patients were tested for VE1 
heterogeneity using a tissue microarray generated from all available blocks (n = 100 
blocks). Results: Inter-observer agreement was 100% (kappa = 1.0). Concordance 
between VE1 and V600E mutation was 98.5%. Cohort 1: VE1 positivity (seen in 
13.5%) was associated with older age (p = 0.0175) and MLH1 deficiency (p < 0.0001). 
Cohort 2: VE1 positivity (seen in 12.8%) was associated with female gender (p = 
0.0016), right-sided tumor location (p < 0.0001), higher tumor grade (p < 0.0001) 
and mismatch repair (MMR)-deficiency (p < 0.0001). In survival analysis, MMR status 
and postoperative therapy were identified as possible confounding factors. Adjusting 
for these features, VE1 was an unfavorable prognostic factor. Preoperative biopsy 
staining matched resections in all cases except one. No heterogeneity was found 
across any primary/metastatic tumor blocks. Conclusion: VE1 is highly concordant 
for V600E and homogeneously expressed suggesting staining can be analysed on 
resection specimens, preoperative biopsies, metastatic lesions and tissue microarrays.
INTRODUCTION
The BRAF proto-oncogene is a serine-threonine 
kinase that is mutated in approximately 10% of colorectal 
cancers [1]. The most common mutation is a thymidine-
adenine transversion in the kinase domain of the protein 
resulting in a V600E amino acid. This leads to constitutive 
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activation of MAPK signaling and consequently to cell 
growth and proliferation.
In colorectal cancer, BRAF plays multifaceted roles 
in tumor progression, diagnosis, prognosis and may act 
as a predictor of response to combined targeted therapies. 
Concerning the molecular classification of colorectal 
cancer and tumorigenesis, BRAF mutation is an early 
event hypothesized to give rise by way of oncogene-
activated senescence to the development of sessile serrated 
adenomas (SSA) and to the hypermethylator phenotype 
[2]. SSA may eventually develop into colorectal cancers 
with a high-degree of microsatellite instability (MSI-H); 
BRAFV600E mutations are over-represented in this group 
with a frequency of 40-60% [1]. Importantly, BRAFV600E 
is used as an exclusion criteria in the case of suspected 
Lynch syndrome, as this mutation does not appear in 
Lynch syndrome patients with the MSI-H phenotype 
caused by germline mutations in factors of the mismatch 
repair (MMR) system [3].
The low frequency of BRAFV600E in colorectal 
cancer has compromised the assessment of its prognostic 
effect, which can only reliably be determined in large 
and adequately powered studies. However, results 
from the CAIRO-2 [4], CRYSTAL and OPUS trials [5] 
where patients were treated with various combination 
therapies, confirmed that BRAF mutation confers a worse 
progression-free and/or overall survival. Retrospective 
analyses on studies of patients with metastatic disease 
receiving anti-EGFR therapies have shown similar results 
independent of treatment arm [4, 6]. BRAF mutations 
have also been identified as having a detrimental effect 
on prognosis in microsatellite stable (MSS) or MSI-H 
colorectal cancer cohorts, but results are conflicting [7-
10].
BRAF mutational status may play a role in 
determining response to treatment. For example, the small 
molecule inhibitor PLX4032 (Vemurafenib) is specific 
for the BRAFV600E oncoprotein and is a logical choice 
for targeted therapy. Although first results in metastatic 
colorectal cancer trials show only modest and short-term 
results [11] combined anti-BRAFV600E and anti-EGFR 
therapy have shown acceptable tolerance and encouraging 
first response rates [12, 13].
Assessment of BRAF mutation is routinely 
performed by PCR-based methods. Recently, a 
commercial monoclonal antibody (clone VE1) targeting 
the mutant protein has been made available and has been 
shown to perform with a high sensitivity and specificity 
[14]. Here, we aim to: (1) confirm the performance of VE1 
in terms of inter-observer agreement and concordance 
with mutational status, (2) thoroughly investigate the 
heterogeneity of VE1 expression in primary tumor and 
metastases, and (3) determine the prognostic effect of VE1 
in colorectal cancer.
RESULTS
Pilot study
Cell lines
There was 100% concordance between gene 
mutation status and VE1 staining, with V600E mutated 
cell lines COLO-205 and HT-29 cells staining positive and 
HCT-15, LS174, HCT-116, LS180, SW480 and SW620 
showing no immunohistochemistry expression.
Figure 1: Four pre-selected cases of colorectal cancer with known mutational status for V600E (one wild-type and 
three mutated) were sectioned and the whole tissue slides stained for VE1. Pyrosequencing was performed again to confirm 
the BRAF status. Concordance between VE1 positivity and BRAFV600E status was 100%.
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Whole tissue sections
Next, we identified one wild-type and 3 mutated 
colorectal cancer patients from the pilot cohort and 
sectioned whole tissue slides. There were no adjacent 
regions of pre-neoplastic tissue. VE1 staining was 
performed and compared to pyrosequencing results. 
Immunohistochemistry results identified three V600E 
positive and one negative tumor. Pyrosequencing 
confirmed these results (Figure 1). Whole tissue 
slides from an additional seven cases underwent VE1 
immunohistochemistry. There was no heterogeneity, 
although weaker staining could be observed toward the 
invasion front in some cancers (not shown). Based on 
these results, we reasoned that tissue microarray analysis 
of VE1 expression could be carried out.
Tissue microarray of pilot cohort
An ngTMA was constructed from colorectal 
cancers, malignant melanomas and thyroid carcinomas. 
Representative immunohistochemistry stains for colorectal 
cancers and normal colonic mucosa are found in Figure 
2. VE1 immunohistochemistry ranged from negative to 
weak, moderate and strong cytoplasmic staining of the 
colonic cancers, while normal tissues were negative for 
any cytoplasmic staining. Weak staining, which was found 
in 2/18 (11.1%) VE1 positive colorectal cancers, was also 
considered a positive result. Positive expression in thyroid 
cancers and melanoma tissues was always moderate to 
strong.
The sensitivity and specificity of VE1 for V600E 
compared to pyrosequencing results and scored by each 
of three observers is shown in Supplemental Table 1. 
All three observers classified the same single BRAF 
wild-type case as positive for VE1. This case had only 
spotty, discontinuous staining of VE1 in a carcinoma with 
mucinous histology (Supplemental Figure 1). A second 
pyrosequencing was performed to re-confirm the wild-
type status. Sensitivity ranged from 92.86% to 93.33% due 
to different number of evaluated cases, while specificity 
was 100%. Inter-observer agreement was 100% (kappa = 
1.0). BRAF mutational status from all thyroid (n = 8) and 
melanoma (n = 23) cases were correctly detected by all 
observers.
Prognostic cohorts
Cohort 1 (Munich, Germany)
Cohort 1 was comprised of primary colonic 
carcinomas (no rectal cancers) from stage I-IV patients. 
Of the 259 patients included on the tissue microarray (six 
punches per patient), 224 (86.5%) were VE1 negative 
and 35 (13.5%) were VE1 positive. Of these positive 
cases 3 (8.6%) showed a weak expression. Patients with 
VE1 positive cancers were more likely to be older (69.4 
years compared to 64.3 years; p = 0.0175) and had more 
frequent MLH1 deficiency (45.7% of VE1 positive versus 
4.5% VE1 negative cases; p < 0.0001). There was no effect 
Table 1: Association of VE1 staining with clinicopathological features and survival time in Cohort 1 (German cohort, 
only colon cancers)
Feature Negative (n=224; 86.5%)
Positive 
(n=35; 13.5%) P-value
Patient age (years) Mean (min, max) 64.3 (25-91) 69.4 (34-90) 0.0175
Gender Male 125 (55.8) 14 (40.0) 0.0812
Female 99 (44.2) 21 (60.0)
Tumor location Right-sided 32 (14.3) 8 (22.9) 0.1919
Left-sided 192 (85.7) 27 (77.1)
pT pT1-2 8 (3.6) 1 (2.9) 0.8301
pT3-4 216 (96.4) 34 (97.1)
pN pN0 133 (59.6) 21 (60.0) 0.9679
pN1-2 90 (40.4) 14 (40.0)
pM pM0 193 (86.6) 31 (88.6) 0.742
pM1 30 (13.5) 4 (11.4)
Tumor Grade G1-2 201 (89.7) 32 (91.4) 0.7561
G3-4 23 (10.3) 3 (8.6)
Post-operative therapy None 134 (63.5) 23 (69.7) 0.49
Treated 77 (36.5) 10 (30.3)
MLH1 expression Deficient 10 (4.5) 16 (45.7) <0.0001
Proficient 214 (95.5) 19 (54.3)
Survival All patients (5-year %) 66.8 (61-72) 63.7 (45-78) 0.669
pM1 patients (median) 24 (14-33) 4.5 (0-12) <0.0001
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on survival. However, within the metastatic patients only, 
VE1 positivity was associated with significantly worse 
overall survival (median 4.5 months versus 24 months; p 
< 0.0001). Of note, only four patients had concomitant 
VE1 positive staining. Results are summarized in Table 1 
and Figure 3a, 3b.
Cohort 2 (Bern, Switzerland)
Cohort 2A: VE1 in a multi-punch tissue 
microarray of 226 colorectal cancer patients 
(resections)
Colorectal cancers from 226 patients were mounted 
onto a multi-punch 0.6 mm core tissue microarray, 
including 195 VE1 negative (87.1%) and 29 VE1 positive 
cases (12.8%). Weak staining occurred in 3/29 positive 
cases (10.3%). Results are found in Table 2. All cores 
from the same patient stained identically (all positive or 
Table 2: Association of VE1 staining with clinicopathological features and survival in Cohort 2 (Swiss, colon and rectal 
cancers)
Feature Surgical resections (n=226) P-value
Preoperative biopsies 
(n=118) P-value
Wild-type 
(n=197;
 87.1%)
Mutation 
(n=29;
 12.8%)
Wild-type 
(n=104; 
87.8%)
Mutation 
(n=14; 
12.2%)
Age (years) Median (min, max) 70 (50-91) 75 (56-87) 0.0768 71.6 (31-91) 80 (56-87) 0.0703
Gender Male 127 (65.1) 10 (34.5) 0.0016 66 (63.5) 6 (42.9) 0.1378
Female 68 (34.9) 19 (65.5) 38 (36.5) 8 (57.1)
Primary histological 
subtype Adenocarcinoma 169 (85.8) 21 (72.4) 0.0662 91 (87.5) 9 (64.3) 0.0233
Mucinous 28 (14.2) 8 (27.6) 13 (12.5) 5 (35.7)
Tumor location Left 98 (50.5) 4 (13.8) <0.0001 48 (47.1) 2 (14.3) 0.0001
Rectum 33 (17.0) 2 (6.9) 25 (24.5) 0 (0.0)
Right 63 (32.5) 23 (79.3) 29 (28.4) 12 (85.7)
pT pT1-2 33 (16.8) 7 (25.1) 0.3305 25 (24.0) 2 (14.3) 0.4148
pT3-4 164 (83.3) 22 (75.9) 79 (76.0) 12 (85.7)
pN pN0 79 (40.1) 13 (40.1) 0.6286 43 (41.4) 6 (42.9) 0.9142
pN1-2 118 (59.9) 16 (55.2) 61 (58.7) 8 (57.1)
pM pM0 174 (88.3) 25 (86.2) 0.7427 92 (88.5) 11 (78.6) 0.297
pM1 23 (11.7) 4 (13.8) 12 (11.5) 3 (21.4)
cM cM0 136 (73.5) 20 (71.4) 0.8163 73 (74.5) 9 (64.3) 0.42
cM1-2 49 (26.5) 8 (28.6) 25 (25.5) 5 (35.7)
Tumor grade G1-2 151 (77.0) 11 (37.9) <0.0001 80 (78.4) 1 (7.1) <0.0001
G3 45 (23.0) 18 (62.1) 22 (21.6) 13 (92.9)
Lymphatic invasion Absent 34 (24.1) 6 (30.0) 0.5686 26 (27.7) 2 (16.7) 0.416
Present 107 (75.9) 14 (70.0) 68 (72.3) 10 (83.3)
Venous invasion Absent 63 (43.2) 6 (31.6) 0.3472 49 (51.6) 4 (33.3) 0.012
Present 83 (56.8) 13 (69.4) 46 (48.4) 8 (66.6)
Perineural invasion Absent 101 (84.2) 14 (87.5) 0.7289 83 (89.3) 10 (82.3.3) 0.5445
Present 19 (15.8) 2 (12.5) 10 (10.8) 2 (16.7)
Peritumoral budding Mean (min-max) 6.3 (0-38) 8.3 (0.9-85) 0.1955 6.2 (0-28.5) 10.9 (3.4-20.1) 0.0694
Intratumoral budding Mean (min-max) 4.8 (0.1-42.3) 12.1 (0.5-43.3) 0.0044 4.3 (0.2-17.7) 18.1 (0.6-37.1) 0.0152
Post-operative therapy None 148 (76.7) 19 (65.5) 0.194 83 (80.6) 11 (78.6) 0.859
Treated 45 (23.3) 10 (34.5) 20 (19.4) 3 (21.4)
MMR status Proficient 154 (92.8) 12 (44.4) <0.0001 85 (91.4) 5 (35.7) <0.0001
Deficient 12 (7.2) 15 (55.6) 8 (8.6) 9 (64.3)
Survival All patients 58.1 (49-66) 57.3 (34-75) 0.2379 61 (48-71) 45 (17-69) 0.0609
pM1 41 (16-65) 66 (5-95) 0.5874 48.7 (12-78) 66.7 (5-95) 0.7442
pM0 58.8 (50-67) 48 (24-69) 0.1743 63.6 (51-74) 37.4 (9-66) 0.0174
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all negative). Patients with VE1 positive staining tended 
to be older (75 versus 70 years; p = 0.0768), were more 
likely female (p = 0.0016), had a higher frequency of 
mucinous cancers (p = 0.0662) and right-sided tumor 
location (p < 0.0001). Tumors were of higher tumor 
grade (p < 0.0001), had significantly more intratumoral 
budding (p = 0.0044) and had a significantly greater 
frequency of MMR deficiency (p < 0.0001). There was no 
survival difference in univariate analysis. We next looked 
at MMR-deficient versus proficient cases. As seen in the 
Kaplan-Meier plots (Figure 3c, 3d), VE1 appears to have 
a negative prognostic effect in MMR-deficient patients 
(p = 0.0624), although this result did not reach statistical 
significance, likely due to the small sample size. Secondly, 
Figure 2: Representative images of colorectal cancers stained for VE1. Left panels: Hematoxylin and Eosin of corresponding 
cases. Right panels: VE1 staining in colorectal cancers and normal mucosa. Staining was in the epithelium and cytoplasmic. Expression 
ranged from strong to moderate/weak and negative. Normal mucosa was negative for cytoplasmic staining although some nuclear positivity 
was frequently seen.
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evaluating postoperatively treated versus untreated 
patients, VE1 appeared to play a more important role only 
in the untreated patient subgroup (p = 0.082). Since also 
palliative patients are included in the treatment group, we 
performed a final analysis on non-metastatic/treated and 
untreated patients and saw similar, albeit significant results 
(p = 0.0225) (Figure 3e, 3f). This unfavorable prognostic 
effect was maintained after adjusting for pT and pN (Table 
3).
Cohort 2B: VE1 in a single punch tissue 
microarray of matched pre-operative biopsies
In order to determine whether the information on 
BRAF status could already be determined at the earliest 
time point, namely at preoperative biopsy, a tissue 
microarray of 1.0 mm biopsy cores was constructed and 
VE1 staining compared to the surgical specimen. Of the 
patients in cohort 2A, 118 had available preoperative 
biopsies. A tissue microarray with 1.0 mm diameter cores 
was constructed. Results are found in Table 2. Patients 
with VE1 positive staining tended to be older (71.6 
versus 80 years; p = 0.0703), had tumors with mucinous 
histology (p = 0.0233) and a predominance for right-sided 
tumor location (p = 0.0001). No VE1 positive tumors 
were found in the rectum. VE1 positive cancers were of 
higher tumor grade (p < 0.0001), had significantly more 
intratumoral budding (p = 0.0152), showed more frequent 
venous invasion (p = 0.012) and had significantly more 
frequent MMR-deficiency (p < 0.0001). Overall 5-year 
survival rate was 45% versus 61 % in VE1 positive versus 
negative cases (p = 0.0609). Stratifying patients into non-
metastatic and metastatic subgroups, 5-year survival in 
the non-metastatic cases was significantly lower in VE1 
positive patients (5-year survival 37.4% versus 63.6%; 
p = 0.0174). Most importantly, all 12 patients found to 
have VE1 positive cancers in the preoperative biopsy also 
showed VE1 positivity in the corresponding resection 
specimen. Only a single case was discordant between 
biopsy (VE1 negative) and resection (VE1 positive).
Matched primary and metastatic lesions
Here we perform a comprehensive heterogeneity 
assessment within/between primary cancers and within/
between matched metastatic sites. Utilizing several 
different regions from all tumor blocks of primary cancers 
and metastases, 13 patients and 100 tumor blocks were 
included. In total 123 different tumor regions were 
analyzed. Four patients were identified as V600E in 
primary cancers-, with no heterogeneity among different 
tumor blocks of the same cancer. The same four cases 
were found to have mutated metastases.
DISCUSSION
In this study we show that the concordance between 
VE1 and BRAFV600E mutations as well as the inter-
observer agreement of VE1 is high. Staining for VE1 is 
homogeneous throughout the tumor and corresponding 
metastases suggesting that either tissue can be used for 
assessment. Finally, VE1 has an unfavorable prognostic 
effect on outcome but postoperative therapy may play a 
major confounding role in the assessment.
VE1 staining can be negative, weak, moderate or 
strong. Sensitivity for V600E was 92.9% to 93.3% and 
specificity was 100%. Nearly all published studies to 
date have described high rates of concordance. Day and 
colleagues report >98% sensitivity and specificity in a 
large cohort of 477 patients [19]. Dvorak et all have a 
98.6% sensitivity and 99.1% specificity in their series of 
more than 300 patients [20], while Vakiani et al report 
93.7% and 95.6% sensitivity and specificity [21]. Despite 
these high values, the interpretation of VE1 staining 
can be challenging in the case of weak positivity, which 
according to our data occurs in approximately 10% of 
all positive cases. Standardization of fixation times, 
staining protocols as well as optimization for different 
autostainers (Ventana Benchmark versus Leica Bond) 
will be necessary for reliable implementation in routine 
diagnostics [20, 22, 23]. This is underlined by results from 
Lasota and colleagues. While most studies have performed 
immunohistochemistry using the Ventana Benchmark, 
Table 3: Multivariable survival analysis showing the unfavorable prognostic effect of VE1 positivity in the 
subgroup of postoperatively untreated and non-metastatic patients 
Feature Surgical resection specimen
HR (95%CI) P-value
VE1 2.23 (1.1-4.6) 0.027
pT 0.93 (0.45-1.93) 0.8482
pN 1.28 (0.78-2.12) 0.3293
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this group performs VE1 staining using a Leica Bond-
Max. Sensitivity and specificity are reported at 85% and 
68%, respectively even when only moderate to strong 
expression are considered [23].
Heterogeneity of VE1 staining, regardless of 
intensity is minimal. This statement is underlined by 
three different evaluations: on whole tissue sections, 
preoperative biopsies and all tumor blocks from metastatic 
colorectal cancers. Taken together, it appears that either 
material can be used for VE1 testing suggesting also that 
BRAF mutation testing can already be made at the earliest 
time point of diagnosis. Finally, tissue microarray studies 
can be reliably performed to screen for possible BRAF 
mutated cases for research purposes.
This homogeneity within primary tumors and their 
matched metastatic lesions also underlines previous works 
suggesting that BRAF mutation is a driver and an early 
event in tumorigenesis for cancers deriving through the so-
called serrated pathway [2]. However, different molecular 
classifications of colorectal cancer deduced by way of 
bioinformatic analyses of DNA aberrations and gene 
expression changes have identified more than one cluster 
Figure 3: Kaplan-Meier survival curves and log-rank test showing the effect of VE1 positivity on overall survival. a. 
German cohort- all patients, b. German cohort- metastatic patients (p < 0.0001), c. Swiss cohort- mismatch repair (MMR)-deficient patients 
(p = 0.0624), d. Swiss cohort- MMR-proficient patients, e. Swiss cohort - non-metastatic patients receiving postoperative therapy, f. Swiss 
cohort- non-metastatic patients not receiving postoperative therapy (p = 0.0225).
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involving BRAF mutation [24]. In our study, we show that 
patients with VE1 positive immunohistochemistry show 
the typical characteristics associated with BRAF mutated 
cancers. These include older patient age, female gender, 
mucinous histology, right-sided tumor location, higher 
tumor grade, and MMR-deficiency. These features are 
frequently reported in cases where mutation is detected by 
genetic analysis [9, 25, 26].
We show the unfavorable prognostic effect of 
VE1 in two subgroup analyses. In the German cohort, 
metastatic patients with VE1 have a significantly worse 
outcome than VE1 negative patients, while in the Swiss 
cohort, the prognostic stratification by VE1 is seen in non-
metastatic patients only. We believe this difference is due 
to the change in post-operative therapy over time. While 
the older German cohort mostly includes patients from 
the 1990s receiving 5-FU alone in most cases, the Swiss 
cohort from the mid to late 2000s received combination 
therapy and considerably more frequent monoclonal 
antibody therapy in the metastatic setting. This change 
in therapy seems to have had a major impact on survival 
which surpasses the effect of BRAF mutation.
The use of VE1 in diagnosis of Lynch syndrome 
has been raised by several groups. Capper and colleagues 
studied 91 MSI-H patients. In their series, none of the 
tumors from patients carrying MMR germline mutation 
showed positive VE1 staining suggesting that VE1 
expressing colorectal cancers could be excluded from 
further germline mutation testing [27]. Tumors found to 
be VE1 positive showed concomitant MLH1/PMS2 loss, 
exclusively. Toon and colleagues propose to integrate 
VE1 immunohistochemistry as part of standard screening 
in routine diagnostics alongside standard MMR protein 
analysis (MLH1, MSH2, MSH6 and PMS2 staining) [28]. 
Together with clinical data, this additional information 
would on the one hand lead to high sensitivity and 
specificity for detection of patients for germline testing 
while on the other help with identifying those patients 
with MMR proficient cancers who may have a more 
unfavorable prognosis. In Germany and Switzerland, 
BRAF mutation testing is only recommended for tumors 
showing MLH1 loss by immunohistochemistry [29]. In 
this context, VE1 staining could be performed in a first 
step and followed-up by PCR only in the case of weak/
inconclusive staining. However, a universal screening 
approach as discussed by Toon et al would not only have 
advantages for diagnostic practice but also for carrying 
out future prognostic and possible predictive biomarker 
studies.
Although some aspects of this study are confirmatory 
with regard to VE1 staining, several points add to the 
current knowledge. Firstly, we have performed a thorough 
evaluation of tumor heterogeneity by evaluating whole 
tissue sections of surgical specimens, multi-punch tissue 
microarrays, preoperative biopsies and their matched 
resections and an in-depth analysis of all tumor blocks 
(primary and metastatic) from patients with metastatic 
disease at one or more sites. Second, two independent 
collectives were investigated totaling more than 500 
patients for analysis of VE1 staining, histomorphological 
features and overall survival, underlining the expected 
relationships of BRAF mutation.
In summary, VE1 immunohistochemistry is 
strongly concordant with BRAFV600E. High inter-observer 
agreement can be achieved. VE1 staining is homogeneous 
indicating that any primary tumor or metastatic sample can 
be tested. Moreover, VE1 is appropriate for use on tissue 
microarrays and is an excellent screen for BRAF mutation 
on large collectives. However, caution should be used 
when evaluating weakly stained tumors and such cases 
should still be validated by another method.
MATERIALS AND METHODS
Patients and Cohorts
Pilot cohort: colorectal cancers, thyroid cancers and 
malignant melanoma tissues
The database of the Institute of Pathology, 
University of Bern was searched for retrospective cases 
having previously undergone BRAF gene testing by 
pyrosequencing or Sanger sequencing. Sixty-five patients 
were identified, the diagnostic slides were retrieved, the 
case was reviewed and representative blocks were selected 
for the study. The cohort included 34 colorectal cancers 
(21 mutated and 13 wild-type), 23 malignant melanoma 
(10 mutated and 13 wild-type) and 8 thyroid cancers (5 
mutated and 3 wild-type), all resected between 2010 and 
2014 at the Bern University Hospital, Switzerland.
Cohort 1: German colorectal cancer patients stage I-IV
A well-characterized cohort of 341 non-consecutive 
colon cancers treated at the Department of Surgery at the 
Technical University Munich hospital, Munich, Germany, 
between 1993 and 2005 was originally considered for 
this study [15]. Due to availability of material for tissue 
microarray construction, the final number of patients was 
259. Clinical and pathological features included age at 
diagnosis, gender, tumor location, pT, pN and pM stage 
(TNM 6th edition), R classification, and tumor grade. 
Information on post-operative therapy was available in 
244 patients. There were no rectal cancer cases and no 
patients received pre-operative therapy. MLH1 protein 
expression was available for all tumors. Seven patients 
had an IBD-associated colorectal cancer. Overall 5-year 
survival was 66.4% (95%CI: 60-72). The clinical endpoint 
of interest was distant metastasis and overall survival.
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Cohort 2: Bern colorectal cancer patients stage I-IV
Cohort 2A: A retrospective collective of more than 
700 primary colorectal cancer patients treated at the Bern 
University Hospital between 2002 and 2011 was originally 
considered and the first 335 cases were entered into the 
study. Due to access to the original diagnostic slides, all 
cases were re-reviewed by two expert gastrointestinal 
pathologists (A.L., H.E.D.) supported by a senior resident 
(V.H.K.) according to the TNM 7th edition. Clinical 
and histopathological features included patient age at 
diagnosis, tumor location, pT, pN, pM, tumor grade 
(WHO 4th edition), the presence of lymphatic invasion, 
venous invasion, perineural invasion, peritumoral as well 
as intratumoral budding scored using the average of buds 
across 10 high-power fields [16], and MLH1 expression. 
Exact therapy and long-term follow up were obtained for 
all patients. Patients having received preoperative therapy 
or those with insufficient tissue for subsequent tissue 
microarray construction were excluded, leaving n = 226 
patients for analysis. The clinical endpoint of interest was 
overall survival.
Cohort 2B: From these 226 patients, 118 patients 
were found to have a matched preoperative biopsy and 
sufficient material for tissue microarray construction 
without compromising the entire tumor material. The 
5-year overall survival rate was 58.8% (95%CI: 48-68).
Matched primary and metastatic lesions
Thirteen colorectal cancer patients with metastases 
at the time of primary diagnosis (pM1) were identified 
from Cohort 2. All cases were re-reviewed. Every primary 
tumor block and every metastatic lesion were included 
into subsequent analysis. Additionally in three cases 
more than 1 tumor region per block was also investigated. 
Hence the total number of primary and metastatic tumor 
regions captured for this tissue microarray was n = 123. 
Additional clinicopathological information for the cohort 
included age at diagnosis, gender, tumor grade, presence 
of venous and lymphatic invasion. All patients had a post-
operative systemic antitumoral therapy.
Patient characteristics for cohorts 1 to 4 are listed in 
Supplemental Table 2 and 3
Next-generation tissue microarray construction
All tissues were fixed in 10% buffered formalin 
and stored in a cool and dry environment. For all patient 
cohorts, a tissue microarray was constructed using the 
next-generation tissue microarray approach (ngTMA) 
[17]. First, diagnostic H&E slides corresponding to 
each case were re-reviewed. The most representative 
one to three H&E slides were selected for each cohort 
and scanned (Pannoramic P250, 3DHistech). Slides 
were uploaded onto a digital slide management interface 
(Case Center, 3DHistech) and annotated using a tissue 
microarray annotation tool of various sizes (0.6mm or 
1.0mm) and colors to designate the different histological 
areas for capturing in the TMA (Supplemental Figure 2). 
Next, corresponding donor blocks were loaded into the 
automated tissue arrayer (TMA Grandmaster), aligned 
with the digital slide and its annotations, and finally 
cored for TMA construction. Details of the ngTMA core 
numbers and sizes can be found in Supplemental Table 
4. The use of all material in this study was approved by 
the corresponding ethics committee (Munich, Germany: 
Klinikum rechts der Isar (no. 1926/7), Bern, Switzerland: 
Ethics commission of the canton of Bern (200/14)).
Cell lines
Eight well-established human colorectal cancer cell 
lines were included in this study (HCT15, SW620, LS174, 
LS180, SW480, HCT116, COLO205, HT29). Cells were 
harvested after trypsinization in a solution of 0.05% of 
Trypsin-EDTA and washed two times in phosphate 
buffered saline (PBS). Four drops of serum were added 
to the cell sediment and mixed to dissolve the pellet. 
One drop of thrombin was then added to the solution and 
incubated for 2 min at room temperature until a clot was 
formed. The clot was transferred into a plastic cassette and 
incubated in 4% formalin. After dehydration in graded 
alcohols and immersion in xylene, paraffin-embedding of 
each cell line was undertaken and a cell block was made. 
A tissue microarray containing two punches per cell lines 
was constructed (total = 16 cores).
Immunohistochemistry and evaluation of BRAF 
VE1
BRAF clone VE1 (Ventana Medical Systems, 
Tucson, AZ, USA) immunohistochemistry was first 
performed on the cell line TMA and pilot cohort by first 
sectioning the TMA block at 3 µm. Testing was performed 
using a Benchmark Ultra Platform (Ventana Medical 
Systems, Tucson, AZ, USA). The OptiView DAB IHC 
Detection Kit (Ventana Medical Systems, Tucson, AZ, 
USA) was applied for optimal visualization. Samples 
were baked at 62°C for 20 min. Deparaffinized sections 
were rehydrated in EZ Prep® (Ventana Medical System, 
Tuczon, AZ, USA) at 72°C. Antigen retrieval was done 
by heating CC1 solution (pH 9.0) for 72min. Endogenous 
peroxidase activity was blocked with H2O2 solution 
3% (Ventana Medical System, Tuczon, AZ, USA). The 
primary antibody was incubated at 36°C for 40 min. 
Finally, the slides were counterstained in hematoxylin and 
bluing reagent (Ventana Medical System, Tucson, AZ, 
USA)
VE1 was specific for epithelium. A result was 
considered positive when expression was cytoplasmic and 
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ranged from weak to moderate and strong. Some positive 
nuclear staining was found in normal epithelium and more 
rarely in tumor cells. However, this staining pattern is not 
considered a positive VE1 result and the significance of 
this finding is unknown [14, 18]. The pilot cohort was 
evaluated by three observers with different histopathology 
experience (SC, AL, IZ). After determining agreement, 
sensitivity and specificity of VE1 for V600E mutation 
in the pilot cohort, the remaining tissue microarrays 
underwent the same immunohistochemistry protocol.
Molecular analysis
For cases requiring re-confirmation of BRAF 
mutational status, one 10 µm tissue section was cut 
from the tumor block. DNA was extracted using 
standard protocols (FFPE Kit, Qiagen), BRAF 
(exon 15, V600E) mutations were interrogated by 
pyrosequencing. Primers were the following: forward 
5’-TGAAGACCTCACAGTAAAAATAGG-3’, 
biotinylated reverse 5’- TCCAGACAACTGTTCAA 
ACTGAT-3’ and sequencing 5’- TGATTTTGGTCTAGC 
TACA-3’.
Statistical analysis
Association of categorical variables and VE1 
expression was performed using the Chi-Square test. 
Continuous variables were analyzed using the Wilcoxon 
or Kruskal-Wallis test. Log-rank tests together with 
Kaplan-Meier curves highlight univariate survival time 
analysis, while multivariable Cox regression analysis after 
verification of the proportional hazards assumption was 
undertaken after adjusting for pT, pN and post-operative 
therapy. Hazard ratios (HR) and 95% CI were used to test 
the effect size. All p-values were two-sided and considered 
significant when p < 0.05. Analyses were performed using 
SAS (V9.2, the SAS System, Cary, NC).
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